electroCore, Inc. (NASDAQ: ECOR) disclosed that it has commenced enrollment in the study to analyze the effect of Non-Invasive Electrical Vagus Nerve Stimulation (nVNS) on Respiratory Symptoms due to COVID-19. This study is also called SAVIOR-1and the study is backed by electroCore.
The firm took the important step as it started the enrollment to get a clear view of nVNS and how it can assist patients who suffer from COVID-19 breathing difficulties. nVNS will be a breakthrough for the scientists and researchers who are studying the COVID-19 and its new treatment which will be helpful in the study of respiratory functions.
ECOR is hoping that nVNS will provide a new cure for the sufferers who are experiencing breathing difficulties due to COVID-19. Currently, the world is facing a pandemic, and researchers and other medical authorities are striving to bring new cures for the novel coronavirus. Recently, researchers are starting to take interest in nVNS and its potential to treat breathing difficulties in COVID-19 patients.
Furthermore, gammaCore SapphireTM CV (nVNS) is unique in its competence to be utilized at an early stage throughout the disease, at home, or in the health care facilities. It has also got the EUA from FDA in July of 202o for the treatment of sufferers who are experiencing the symptoms of COVID-19.
The enrollment news in the nVNS study has excited the stock of the firm as its share rose 5.67% at $2.23 at the time of writing on Wednesday. electroCore revealed that it is moving forward with no information on the novel coronavirus. It is waiting for the results of this study so that the world can get the new cure for the respiratory problems of COVID-19 sufferers. electroCore has a total market capitalization of $99.06 million at the time of writing.